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Abstract
To date, many studies conducted in the Chinese population have determined the correlation between the tumour necrosis factor-a (TNF-
a)-238G/A, -308G/A, -857C/T and -863C/A polymorphisms and persistent hepatitis B virus (HBV) infection. However, their results remain
inconclusive. With the aim of conﬁrming this correlation, we performed a meta-analysis of 19 studies. The dichotomous data are presented
as the OR with a 95% CI. The results of our study indicate that carriers of the TNF-a-857T allele among the pooled Chinese population
were more likely to show spontaneous clearance of HBV (T vs C: OR = 0.824, 95% CI = 0.713–0.953, p 0.009; TT vs CC: OR = 0.701,
95% CI = 0.507–0.970, p 0.032; TC vs CC: OR = 0.804, 95% CI = 0.683–0.947, p 0.009; TT + TC vs CC: OR = 0.835, 95% CI = 0.716–
0.974, p 0.021). The TNF-a-308A allele was associated with signiﬁcantly reduced persistent HBV infection risk in the Chinese (A vs G:
OR = 0.585, 95% CI = 0.456–0.751, p 0.002; AG vs GG: OR = 0.519, 95% CI = 0.341–0.789, p <0.000; AA + AG vs GG: OR = 0.512,
95% CI = 0.339–0.772, p 0.001). Persistent HBV infection susceptibility is associated with the TNF-a-308G/A gene polymorphism in the
Chinese population, whereas HBV clearance is associated with the TNF-a-857C/T gene polymorphism.
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Introduction
Hepatitis B is caused by the hepatitis B virus (HBV) and is a
major global health concern and the most serious type of viral
hepatitis. It can progress to chronic liver diseases, resulting in
cirrhosis or cancer, and is potentially life-threatening. Accord-
ing to a World Health Organization (WHO) report, 2 billion
people worldwide have been infected with the virus, and
approximately 600 000 people die annually because of the
consequences of hepatitis B. According to a report by the
Centers for Disease Control and Prevention (CDC) of the
USA, approximately 90% of infected infants and 30% of
infected children aged <5 years of age become chronically
infected, whereas 2–6% of adults show chronic infection. The
variable pattern and clinical outcome of the infection are
mainly determined by virological, host immunological, genetic
and experimental factors [1].
Multiple cytokines participate in the process of viral
clearance via the host immune response to HBV, including
tumour necrosis factor-a (TNF-a), transforming growth
factor-b and interleukin -10. Tumour necrosis factor-a plays
a key role in various types of viral infections. The TNF-a gene is
located 850 kb telomeric to the class III HLA-DR locus of the
short arm of chromosome 6, and is closely linked to the
human leucocyte antigen (HLA) gene cluster [2]. Tumour
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necrosis factor-a can regulate interferon-c secretion by T
helper type 1 cells and natural killer cells. It is a potent
proinﬂammatory cytokine, mainly produced by activated
macrophages, and exhibits a wide range of biological proper-
ties, including polarization of a T helper type 1 response,
immune response to infectious agents, and direct antiviral
effects [3]. Several lines of evidence indicate that TNF-a is
important for HBV infection. It suppresses HBV expression
and replication in the liver, and so induces HBV clearance.
Moreover, TNF-a affects the expression of HLA-II molecules
and, hence, viral antigen presentation. HLA polymorphisms are
known to be associated with HBV infection outcomes [4].
Recent evidence indicates that TNF-a can induce the non-
cytolytic suppression of HBV expression and replication in the
liver; moreover, it can inhibit the transcriptional activity of the
HBV core promoter in vitro [5]. More than ten single-
nucleotide polymorphisms are present in the HBV promoter
region, such as those at locations -163G/A, -238G/A, -244A/G,
-308G/A, -376G/A, -575A/G, -857C/T, -863C/A, -1031T/C,
-1125G/C and -1196C/T from the transcription start site. To
date, more than 20 studies have investigated the -238G/A,
-308G/A, -857C/T and -863C/A sites in the Chinese popula-
tion but have yielded inconsistent results. This inconsistency is
likely to be, in part, because these studies were limited by the
small sample size and, therefore, may be underpowered for
drawing a comprehensive and reliable conclusion.
Meta-analysis is a powerful method for quantitatively
summarizing the results of different studies. An advantage is
that it increases the sample size, which may reduce the
probability that random error will result in a false-positive or
false-negative association. Therefore, we performed a meta-
analysis with the goal of quantitatively assessing the association
of TNF-a-238G/A, -308G/A, -857C/T, and -863C/A genetic
polymorphisms with persistent HBV infection cases among the
Chinese population.
Materials and methods
Literature search strategy
The Medline, PubMed, Embase, Web of Science and Chinese
Biomedical Literature Database on disc (CBM disc) databases
were searched (the last search was updated on 26 November
2012) using the search terms “hepatitis B” or “HBV”,
“polymorphism”, “Tumour necrosis factor-a” or “TNF-a”.
All searches were retrieved and their bibliographies were
checked for other relevant publications. Review articles and
bibliographies of relevant identiﬁed studies were hand-
searched. Only published studies with full-text articles were
included. The topic of the studies included TNF-a gene
polymorphism and persistent hepatitis B virus infections. The
following types of studies were excluded: meta-analysis,
reviews, studies unrelated to HBV infection and those that
were conducted in non-Chinese patients. When more than
one of the same patient population was included in several
studies, only the study with the largest sample size or the
complete study was used for this meta-analysis. A ﬂow diagram
of the study selection process is shown in Fig. 1.
FIG. 1. A ﬂow diagram of the study
selection process.
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Inclusion and exclusion criteria
The inclusion and exclusion criteria were established on the
basis of discussion and consensus. The inclusion criteria for
patients (diagnostic criteria) were as follows: (i) individuals
who spontaneously recovered without treatment and showed
serological evidence of previous infection (antibodies against
hepatitis B core antigen and hepatitis B surface antigen) with
hepatitis B surface antigen undetectable at two time-points
separated by a minimum of 6 months were self-limiting
infection controls; vaccinated patients were excluded. (ii)
Patients who had been positive for HBV surface antigen for
more than 6 months were included as persistent HBV
infection cases. (iii) Patients who did not show detectable
HBV infection were deﬁned as healthy controls. The inclusion
criteria for studies were as follows: (i) case–control studies; (ii)
studies that aimed to examine the association of the TNF-a-
238, -308, -857 and/or -863 polymorphisms with clearance
and/or susceptibility of persistent HBV infection; (iii) studies
that provided the number of persistent HBV infection cases or
controls and the frequency of TNF-a-238, -308, -857 and/or
-863 genotypes; (4) studies in which the genotype was
tested in healthy controls to ensure their compliance with
the Hardy–Weinberg equilibrium.
The exclusion criteria were as follows: (i) studies that did
not ﬁt the diagnostic criteria; (ii) studies conducted in animals;
(iii) studies that were not case–control studies; (iv) studies that
reported data that were not relevant to the aim of the present
study; (v) studies in which the data of the healthy control
group deviated from the Hardy–Weinberg equilibrium; (vi)
studies that did not include the Chinese Han population.
Data extraction
All of the data were extracted independently by two reviewers
(T.-C. Zhang and Y.-Q. Zhao) according to the pre-speciﬁed
selection criteria. Any disagreement among the authors was
resolved by discussion. The following data were extracted:
study design and period, statistical methods, population, num-
ber of persistent HBV infection cases (including asymptomatic
carriers and chronic liver diseases), self-limiting infection
controls and healthy controls studied, and the study results.
Statistical analysis
Allele frequencies at the TNF-a-238G/A, -308G/A, -857C/T,
and -863C/A single-nucleotide polymorphisms from the
respective studies were determined using the allele-counting
method. A v2 test was used to determine if observed
frequencies of genotypes corresponded to the Hardy–Wein-
berg equilibrium. Statistical analysis was conducted using STATA
9.0 (StataCorp, College Station, TX, USA) and a p-value ≤0.05
was considered statistically signiﬁcant. Dichotomous data are
presented as the OR with 95% CI. Statistical heterogeneity was
measured using the Q-statistic (p≤ 0.10 was considered to be
representative of statistically signiﬁcant heterogeneity). We
also quantiﬁed the effect of heterogeneity using the I2 statistic,
which measures the degree of inconsistency in the studies by
calculating what percentage of the total variation across
studies is due to heterogeneity rather than by chance. A ﬁxed
effects model was used when there was no heterogeneity in
the results of the trials; otherwise, the random effects model
was used. For dichotomous outcomes, patients with incom-
plete or missing data and small sample studies were included in
the sensitivity analyses by counting them as treatment failures.
To establish the effect of clinical heterogeneity between
studies on the conclusions drawn from the meta-analyses, we
conducted a subgroup analysis based on race. Several methods
were used to assess the potential for publication bias. Visual
inspection of asymmetry in funnel plots was conducted. Begg’s
rank correlation method and Egger’s weighted regression
method were also used to statistically assess the publication
bias (p≤ 0.05 was considered to indicate statistically signiﬁcant
publication bias).
Results
Characteristics of studies
There were 19 relevant studies identiﬁed in our search. The
studies comprised 5267 persistent HBV infection cases, 2021
self-limiting infection controls and 804 healthy controls, and
these were included in our meta-analysis. We identiﬁed -
308G/A, -857C/T and -863C/A single-nucleotide polymor-
phisms in our search; the characteristics of each study are
presented in Appendix 1.
Quantitative data synthesis
The aim of this study was to perform a meta-analysis to
quantitatively summarize the results obtained from various
selected studies. Therefore, we compared the persistent HBV
infection cases with healthy controls, and the persistent HBV
infection cases with self-limiting infection controls. We also
compared persistent HBV infection cases with healthy controls
to determine the relationship of TNF-a-238G/A and -308G/A
polymorphisms with persistent HBV infection susceptibility.
Moreover, we compared persistent HBV infection cases with
self-limiting infection controls to discover the association of
TNF-a-238G/A, -308G/A, -857C/T and -863C/A polymor-
phisms with HBV infection clearance. Four genetic models
(allele model, Co-Dominant model, Recessive model and
Dominant model) were performed for each single-nucleotide
polymorphism.
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As shown in Table 1, the carriers of the TNF-a-857 T allele
were more likely to show spontaneous clearance of HBV than
were those carrying the TNF-a-857C allele genotypes, in the
Chinese Han pooled population (T vs C: OR = 0.824, 95%
CI = 0.713–0.953, p 0.009; TT vs CC: OR = 0.701, 95% CI =
0.507–0.970, p 0.032; TC vs CC: OR = 0.804, 95% CI =
0.683–0.947, p 0.009; TT + TC vs CC: OR = 0.835, 95%
CI = 0.716–0.974, p 0.021). However, the TNF-a-238G/A,
-308G/A and -857C/T polymorphisms exhibited no association
with persistent hepatitis B infection clearance in the Chinese
Han population.
We found no evidence of an association between the
TNF-a-238G/A single-nucleotide polymorphisms and the sus-
ceptibility to persistent hepatitis B infection in the pooled
Chinese population (Table 2). As shown in Table 3, the results
of our meta-analysis indicate that TNF-a-308A is signiﬁcantly
associated with reduced persistent HBV infection susceptibility
in the Chinese Han population (A vs G: OR = 0.585, 95% CI =
0.456–0.751, p 0.002; AG vs GG: OR = 0.519, 95%
CI = 0.341–0.789, p <0.000; AA + AG vs GG: OR = 0.512,
95% CI = 0.339–0.772, p 0.001).
Heterogeneity
Heterogeneity among the studies was calculated using the
Q-statistic (Q > 0.10) and the I2 statistic (I = 0.0%). Hetero-
geneity was found in some groups, and therefore, the random-
effects model was used. Importantly, no I2 heterogeneity
exceeding 80.0% was identiﬁed.
Sensitivity analysis
Each single study involved in the meta-analysis was removed
after every test to investigate the inﬂuence of the individual
TABLE 1. Characteristics and tumour necrosis factor-a (TNF-a) -238, -308, -857, -862 polymorphism genotype distributions in
studies included in the meta-analysis
SNPs Authors Year Region Ethnicity Source
Genotypes
PHI SI
HC
Sample size Sample size Sample size p value for HWE
TNF-a-238
(GG/GA/AA) Wang [3] 2012 Nanjing Han Hospital-based 57/5/0 59/2/0 – –
Zhang [13] 2011 Shaanxi Han Hospital-based 180/17/1 – 255/25/0 0.43
Wang [14] 2010 Beijing Han Hospital-based 139/19/0 719/77/2 – –
Kao [15] 2010 Taipei Undescribed Hospital-based 268/6/0 187/7/0 – –
Lu [17] 2004 Beijing Han Hospital-based 203/4/0 138/10/0 – –
Li [18] 2005 Beijing Han Hospital-based 589/64/0 232/12/0 – –
Li [20] 2006 Fuzhou Han Hospital-based 95/26/1 – 42/21/0 0.11
Chen [21] 2010 Hong Kong Undescribed Hospital-based 285/18/1 340/20/1 – –
Chen [23] 2011 Zhengzhou Han Hospital-based 120/6/0 – 115/11/0 0.61
Zhang [19] 2005 Hubei Han Hospital-based 126/5/0 – 121/5/0 0.82
Xing [24] 2007 Shandong Han Hospital-based 135/8/0 – 90/5/0 0.79
Zhang [29] 2004 Hubei Han Hospital-based 126/5/0 157/7/0 – –
TNF-a-308
(GG/GA/AA) Wang [3] 2012 Nanjing Han Hospital-based 51/10/1 51/9/1 – –
Zhang [13] 2011 Shaanxi Han Hospital-based 179/19/0 – 251/28/1 0.82
Wang [14] 2010 Beijing Han Hospital-based 700/92/6 143/15/0 – –
Kao [15] 2010 Taipei Undescribed Hospital-based 221/38/15 154/39/1 – –
Du [16] 2006 Beijing Han Hospital-based 179/15/2 128/10/5 – –
Li [20] 2006 Fuzhou Han Hospital-based 91/31/0 – 44/19/0 0.16
Chen [21] 2010 Hong Kong Han Hospital-based 250/51/3 323/36/2 – –
Chen [23] 2011 Zhengzhou Han Hospital-based 118/8/0 – 111/14/1 0.46
Zhang [19] 2005 Hubei Han Hospital-based 125/6/0 – 108/18/0 0.39
Zhou [25] 2004 Beijing Han Hospital-based 413/43/0 83/20/0 0.32
Jiang [26] 2009 Shanghai Han Hospital-based 145/18/6 – 71/38/10 0.14
Xu [27] 2005 Changsha Undescribed Hospital-based 107/20/0 – 80/10/0 0.58
Zhang [29] 2004 Hubei Han Hospital-based 125/6/0 143/22/0 – –
TNF-a—857
(CC/CT/TT) Kao [15] 2010 Taipei Undescribed Hospital-based 204/67/3 142/51/1 – –
Du [16] 2006 Beijing Han Hospital-based 156/22/18 112/6/25 – –
Li [18] 2005 Beijing Han Hospital-based 479/128/34 173/60/11 – –
Chen [21] 2010 Hong Kong Han Hospital-based 210/79/15 234/105/22 – –
Qiu [22] 2012 Harbin Han Hospital-based 345/189/37 100/70/19 – –
Wan [30] 2010 Guangxi Han Hospital-based 40/29/5 34/26/4 – –
Zhang [28] 2004 Hubei Han Hospital-based 106/22/3 129/36/0 – –
TNF-a–863
(CC/CA/AA) Kao [15] 2010 Taipei Han Hospital-based 120/125/29 107/65/22 – –
Du [16] 2006 Beijing Han Hospital-based 122/50/24 93/23/27 – –
Chen [21] 2010 Hong Kong Han Hospital-based 192/92/20 220/116/25 – –
Qiu [22] 2012 Harbin Han Hospital-based 333/202/36 137/48/4 – –
L iu [28] 2005 Beijing Han Hospital-based 127/50/26 97/24/27 – –
Zhang [29] 2004 Hubei Han Hospital-based 96/29/6 102/60/3 – –
Wan [30] 2010 Guangxi Han Hospital-based 50/15/9 38/24/2 – –
HBV, hepatitis B virus; HC, healthy control; HWE, Hardy–Weinberg equilibrium; PHI, persistent hepatitis B virus infection; SI, self-limiting infection; SNP, single-nucleotide
polymorphism.
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dataset on the pooled ORs. The corresponding pooled ORs
were not materially altered (data not shown), indicating that
our results were statistically strong.
Publication bias
Begg’s funnel plot and Egger’s test were performed to assess
the publication bias of the literature, and no asymmetry of the
funnel plot was found, indicating the absence of a publication
bias in our meta-analysis.
Discussion
A number of recent studies have identiﬁed polymorphisms
that affect susceptibility to infectious diseases. It is believed
that host genetic factors involving genetic polymorphisms are
responsible for the susceptibility and clinical outcomes of
infectious diseases [6], because the differences in the
susceptibility to infection or severity of disease cannot be
solely attributed to the virulence of an organism. The role of
TNF-a in the inﬂammation process has attracted much
attention with regard to the TNF-a gene regulation and the
possibility of synthesis of TNF-a variants. Previous work in
animals has shown that TNF-a suppresses HBV protein
expression and virus replication [7]. Polymorphisms in the
TNF-a gene promoter have been shown to affect cytokine
transcription rate and release. Many studies in the Chinese
population have attempted to identify TNF-a promoter
polymorphisms and their associated effects on persistent
HBV infection; however, the results of these studies are
TABLE 2. Summary about meta-analysis on tumour necrosis factor-a (TNF-a) -238, -308, -857 and -862 in Chinese pooled
population, persistent hepatitis B virus infection versus self-limiting controls
SNP Genetic models Comparisons n
OR (95% CI) Homogeneity Publication bias
OR CI p value Q Ph I² (%) Model P for Begg’ test P for Egger’ test
-238 C/A Allele A/G 7 0.944 0.596–0.495 0.806 12.20 0.058 50.8 Random 1.000 0.700
Co-dominant AA/GG 2 0.895 0.117–6.874 0.915 0.00 0.945 0.0 Fixed 1.000 –
AG/GG 7 0.931 0.573–1.513 0.774 12.89 0.045 53.5 Random 1.000 0.724
Recessive AA/AG+GG 2 0.908 0.119–6.958 0.926 0.01 0.937 0.0 Fixed 1.000 –
Dominant AA+AG/GG 7 0.936 0.579–1.513 0.788 12.75 0.047 52.9 Random 1.000 0.711
-308 C/A Allele A/G 6 0.882 0.635–1.224 0.453 10.38 0.065 51.8 Random 1.000 0.915
Co-dominant AA/GG 6 0.888 0.258–3.061 0.851 10.99 0.052 54.5 Random 0.060 0.267
AG/GG 6 0.909 0.259–3.193 0.882 11.34 0.045 55.9 Random 0.060 0.281
Recessive AA/AG+GG 6 0.812 0.635–1.038 0.096 7.04 0.218 28.9 Random 0.707 0.114
Dominant AA+AG/GG 6 0.842 0.667–1.064 0.149 6.62 0.251 24.5 Fixed 0.707 0.427
-863 C/A Allele A/C 7 1.146 0.931–1.410 0.198 15.15 0.019 60.4 Random 1.000 0.951
Co-dominant AA/CC 7 1.045 0.676–1.616 0.842 12.37 0.054 51.5 Random 0.548 0.282
AC/CC 7 1.364 1.000–1.863 0.050 18.21 0.006 67.1 Random 0.764 0.830
Recessive AA/AC+CC 7 0.948 0.606–1.485 0.817 13.60 0.034 55.9 Random 0.368 0.253
Dominant AA+AC/CC 7 1.222 0.955–1.564 0.112 14.00 0.030 57.1 Random 0.764 0.529
-857 C/T Allele T/C 7 0.824 0.713–0.953 0.009 2.23 0.897 0.0 Fixed 0.368 0.239
Co-dominant TT/CC 7 0.701 0.507–0.970 0.032 3.97 0.410 0.0 Fixed 0.221 0.298
TC/CC 7 0.804 0.683–0.947 0.009 1.35 0.969 0.0 Fixed 0.764 0.767
Recessive TT/TC+CC 7 1.030 0.746–1.423 0.856 8.87 0.181 32.3 Fixed 0.072 0.070
Dominant TT+TC/CC 7 0.835 0.716–0.974 0.021 1.19 0.978 0.0 Fixed 0.368 0.104
SNP, single-nucleotide polymorphism.
Bold: Allele, Recessive and Dominant, Statistically signiﬁcant at p 0.05; Co-dominant: Statistically signiﬁcant at p 0.0167.
TABLE 3. Summary about meta-analysis on tumour necrosis factor-a (TNF-a) -238, -308 in Chinese pooled population,
persistent hepatitis B virus infection versus Healthy controls
SNP Genetic models Comparisons n
OR (95% CI) Homogeneity Publication Bias
OR CI p value Q Ph I² (%) Model p for Begg’ test p for Egger’ test
-238 C/A Allele A/G 5 0.835 0.600–1.162 0.284 2.33 0.675 0.0 Fixed 0.806 0.735
Co-dominant AA/GG 2 2.432 0.252–23.467 0.442 0.25 0.618 0.0 Fixed 1.000 –
AG/GG 5 0.751 0.514–1.098 0.140 2.39 0.665 0.0 Fixed 1.000 0.798
Recessive AA/AG+GG 2 2.612 0.271–25.211 0.407 0.19 0.666 0.0 Fixed 1.000 –
Dominant AA+AG/GG 5 0.776 0.532–1.132 0.188 2.50 0.645 0.0 Fixed 1.000 0.913
-308 C/A Allele A/G 7 0.585 0.456–0.751 0.002 6.35 0.385 5.5 Fixed 1.000 0.752
Co-dominant AA/GG 3 1.041 0.375–2.890 0.939 0.45 0.799 0.0 Fixed 1.000 0.072
AG/GG 7 0.519 0.341–0.789 0.000 13.44 0.037 55.5 Random 1.000 0.929
Recessive AA/AG+GG 3 0.400 0.155–1.030 0.058 0.02 0.989 0.0 Fixed 1.000 0.940
Dominant AA+AG/GG 7 0.512 0.339–0.772 0.001 13.47 0.036 55.5 Random 0.764 0.849
SNP, single-nucleotide polymorphism.
Bold: Allele, Recessive and Dominant, Statistically signiﬁcant at p 0.05; Co-dominant: Statistically signiﬁcant at p 0.0167.
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conﬂicting. It is likely that these inconsistencies are induced
by inadequate sample size.
In this study, the results of the meta-analysis, which
examined the relationship of TNF-a-238G/A, -308G/A,
-857C/T, and -863C/A polymorphisms with persistent HBV
infection in the Chinese population, revealed a signiﬁcantly
decreased risk of susceptibility to persistent HBV infection
because of the presence of the TNF-a-308 A allele in the
Chinese pooled population. The G?A nucleotide substitution
at position -308 in the promoter region of the TNF-a gene
was associated with elevated TNF-a gene transcriptional
activity [8,9]. Interestingly, TNF-a-238G/A, -857C/T or
-863C/A was not found to be associated with spontaneous
HBV clearance in this study. The TNF-a promoter alleles
associated with higher plasma levels, the presence of the
-308A allele (TNF-a-308A/G or A/A) variant, was strongly
associated with the resolution of HBV infection. However,
our results pertaining to the relationship between TNF-a-
308G/A and persistent HBV infection susceptibility differed
from those obtained in the Japanese, Italian, Korean and
Mongoloid populations. There are three reasons for the
differing opinions concerning the TNF-a-308 gene promoter
polymorphisms and chronic HBV patient prognosis. The most
important factor is the sample size, followed by heterogene-
ity, and then the difference in the type of HBV patients
included in each study [10].
The results of this study suggest that TNF-a-857T carriers
are more likely to show spontaneous clearance of HBV.
Whereas previous studies did not ﬁnd an association between
the TNF-a-857T allele and spontaneous HBV clearance, this
study found a common trend within these studies; speciﬁcally,
the OR values of each study were less than 1 when the TNF-a-
857 T and C allele were compared (Fig. 2). This ﬁnding
indicates that the negative results of those studies might be a
result of inadequate sample size. The partial explanation for
this conclusion may be that the OCT1 transcription factor
binds TNF-a-857T but not TNF-a-857C and functionally
interacts with NF-jB, which gives rise to increased TNF-a
production in vivo.
Importantly, the results of this meta-analysis were not
identical to those of two other meta-analyses [11,12]. The
reasons for this inconsistency is probably because each study
had different research subjects; namely, our study was
conducted in Chinese people, whereas the other studies were
conducted in Asian patients. In addition, these studies yielded
the same or overlapping data.
This study has some limitations. First, as only published
studies were included in the meta-analysis, publication bias may
have occurred, even though it was not found by statistical
analysis. Second, meta-analysis essentially remains an observa-
tional study that is subject to the methodological deﬁciencies
of the included studies. Third, this meta-analysis was based on
unadjusted estimates; however, a more precise analysis could
be performed with additional datasets. Finally, the major HBV
genotypes in the Chinese are B and C, but most of the studies
did not analyse them separately, and therefore, because of the
methodological limitations of this study, we could not correct
for this.
FIG. 2. Forest plot of the tumour necrosis factor-a (TNF-a) -857C/T polymorphism and clearance of hepatitis B virus infection(T allele vs C allele).
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In conclusion, despite the limitations mentioned above, the
results of this meta-analysis indicate that in the Chinese
population, persistent HBV infection susceptibility is associated
with TNF-a-308G/A gene polymorphism and that the HBV
clearance is associated with TNF-a-857C/T gene polymor-
phism.
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